Abstract:
OBJECTIVE To provide reference for ovarian function protection in pediatric malignant ovarian tumor patients by summarizing the clinical practice of clinical pharmacists participating in a case of goserelin combined with TC(paclitaxel plus carboplatin) chemotherapy for ovarian function protection in a 10-year-old girl with ovarian Sertoli-Leydig cell tumor(SLCT) after surgery.
METHODS Clinical pharmacists analyzed the case of a 10-year-old girl with moderately-poorly differentiated SLCT who received paclitaxel plus carboplatin chemotherapy combined with goserelin for ovarian function protection after surgery, and explored the mechanism, efficacy and clinical management strategies of gonadotropin-releasing hormone agonist(GnRH-a) in ovarian protection in pediatric patients with ovarian malignant tumors through literature review.
RESULTS Goserelin, a GnRH-a, reduces chemotherapy-induced ovarian damage by suppressing the hypothalamic-pituitary-ovarian(HPO) axis and maintaining the ovaries in a low gonadotropin state. In this case, the strategy of chemotherapy combined with goserelin was implemented based on full informed consent, providing clinical practice experience for ovarian function protection in pediatric rare ovarian malignancies.
CONCLUSION The ovarian protective effect of goserelin is well supported by high-quality evidence in breast cancer patients, whereas evidence for its use in ovarian malignancies and in pediatric and adolescent patients remains limited. This case provides a clinical reference for ovarian function protection in this setting.